Capillary CRP
OtherCRP measured semi-quantitatively using ACTIM-CRP device
NCT Number: NCT06910631
Fever is the leading reason for outpatient consultations among children aged 2 to 9 years. The main concern in fever is severe bacterial infection, particularly for younger children. History and clinical examination do not always differentiate viral infections from bacterial infection. In 20% of febrile children, no infectious focus is found after examination and additional tests are necessary. The first one is measuring C-reactive protein (CRP). The results are obtained in several hours on an outpatient basis, causing long delays before starting treatment and often requiring telephone calls or further consultations. Emergency room use is constantly increasing, generating growing tensions within healthcare facilities, yet a large number of visits are avoidable. Among children visiting the pediatric emergency room, parents reported being referred by their primary care physician in approximately 20% of cases for children aged 1 to 5 years and in 30% of cases for children under one year old. The use of capillary medical device to measure CRP in primary care could reduce this referral rate and help relieve overcrowding in emergency rooms, as well as unscheduled consultation centers and medical analysis laboratories. This would result in a streamlined care pathway, saving time for both physicians and patients, as well as reducing the cost of care for the healthcare system.
Interested in participating?
Request Info3 month–15 year
All sexes
Interventional
Not applicable
Centre médical du Grau D'Agde, Agde, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
CRP measured semi-quantitatively using ACTIM-CRP device
Time frame: Day 1
Referral: Yes/No as reported by the physician
Time frame: Day 7
Referral: Yes/No as reported by the parents
Time frame: Day 1
Referral: Yes/No as reported by the physician
Time frame: Day 7
Referral: Yes/No as reported by the parents
Time frame: Day 1
Referral: Yes/No as reported by the physician
Time frame: Day 7
Referral: Yes/No as reported by the parents
Time frame: Day 1
Total number of tests as reported by the physician
Time frame: Day 7
Total number of tests as reported by the parents
Time frame: Day 1
Qualitative listing of all further tests classified as: biological (CBC, venous CRP, iono/creatininemia, liver function tests, ECBU, others) or imaging (chest X-ray, abdomino-pelvic ultrasound, urinary and renal ultrasound) as reported by the physician
Time frame: Day 7
Qualitative listing of all further tests classified as: biological (CBC, venous CRP, iono/creatininemia, liver function tests, ECBU, others) or imaging (chest X-ray, abdomino-pelvic ultrasound, urinary and renal ultrasound) as reported by the parents
Time frame: Day 7
0-10 visual analog scale
Time frame: Day 7
Minutes: measured as consultation time + examination time and time to inform the family
Time frame: Day 7
0-10 numeric scale
Time frame: Day 1
Antibiotic prescription: Yes/No as reported by the physician
Time frame: Day 7
Antibiotic prescription: Yes/No as reported by the parents
Time frame: Day 7
Days counted upon reaching 24 hours without fever
Time frame: Day 7
euros
Time frame: Day 7
euros
Contact information is provided by the study sponsor or research team.
Centre Hospitalier Universitaire de Nīmes
Other
Optimisation du Parcours de Soins Des Enfants fébriles Par l'Utilisation de la CRP Capillaire en Soins Primaires : Protocole d'un Essai Multicentrique randomisé
Acronym: CRP-CAP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00001373
ALPK1, Autoinflammation
Washington D.C., District of Columbia, United States
View Trial DetailsNCT07578610
Animal Diseases, Body Temperature Changes
Friedrichshain, State of Berlin, Germany
View Trial DetailsNCT07158814
Adverse Event Following Immunisation, Body Temperature Changes
Oakland, California, United States
View Trial DetailsNCT07432893
Body Temperature Changes, Breathlessness
Kolkata, West Bengal, India
View Trial Details